Private equity investment in pharma services accelerated to a near-record level amid tailwinds from M&A-friendly interest rate policies, the opportunity to consolidate drug manufacturers and burgeoning investor appetite for life sciences. In the third quarter, PE firms sealed an estimated 110 pharma services deals, the highest in nearly three years, according to PitchBook’s latest Pharma Services PE Update. That total falls just shy of the record 114 deals reached in Q1 2022. The uptick in pharma services was partly sparked by recent interest-rate cuts, which unleashed a torrent of deal activity across the PE landscape. Trade frictions also contributed to the acceleration in dealmaking, according to PitchBook senior biotech analyst Kazi Helal.
Read the full article: Pharma Services Dealmaking Nears Quarterly Record //
Source: https://pitchbook.com/news/articles/pharma-services-dealmaking-nears-quarterly-record